You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednisone
Accession NumberDB00635  (APRD00340)
Typesmall molecule
Groupsapproved
Description

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
1,2-DehydrocortisoneNot AvailableNot Available
DehydrocortisoneNot AvailableNot Available
PrednisonaSpanishINN
PrednisonumLatinINN
SaltsNot Available
Brand names
NameCompany
Delta-CortefUpjohn
MeticortenNot Available
OrasoneNot Available
Rayos Horizon Pharma
Brand mixtures
Brand NameIngredients
CortabBiotin + Chlorpheniramine Maleate + D-Pantothenic Acid + Inositol + Nicotinic Acid + Prednisone + Pyridoxine Hydrochloride + Thiamine Mononitrate + Vitamin a + Vitamin B2 + Vitamin D + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Metreton TabChlorpheniramine Maleate + Prednisone + Vitamin C
Predniderm TabInositol + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a + Vitamin D2 + Vitamin E
Sterolin LiqBiotin + Fatty Acids Unsaturated + Inositol + Nicotinic Acid + Pheniramine Maleate + Phosphatidyl Choline + Prednisone + Vitamin a Palmitate + Vitamin B2 + Vitamin D2 + Vitamin E
Categories
CAS number53-03-2
WeightAverage: 358.4281
Monoisotopic: 358.178023942
Chemical FormulaC21H26O5
InChI KeyXOFYZVNMUHMLCC-ZPOLXVRWSA-N
InChI
InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Mass Specshow(12.5 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassLipids
ClassSteroids and Steroid Derivatives
SubclassGluco/mineralocorticoids, Progestogins and Derivatives
Direct parentGluco/mineralocorticoids, Progestogins and Derivatives
Alternative parentsHydroxysteroids; Ketosteroids; Cyclohexanones; Tertiary Alcohols; Cyclic Alcohols and Derivatives; Enolates; Polyamines; Primary Alcohols; Aldehydes
Substituents3-keto-steroid; 17-hydroxy-steroid; 11-keto-steroid; 20-keto-steroid; cyclohexanone; tertiary alcohol; cyclic alcohol; ketone; polyamine; enolate; primary alcohol; alcohol; carbonyl group; aldehyde
Classification descriptionThis compound belongs to the gluco/mineralocorticoids, progestogins and derivatives. These are steroids whose structure is based on an hydroxylated prostane moiety.
Pharmacology
IndicationFor the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe (Stevens-Johnson syndrome) erythema multiforme, mycosis fungoides, pemphigus, severe psoriasis, acute adrenocortical insufficiency, Addison's disease, secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with neoplasms, nonsuppurative thyroiditis, ulceratice colitis, Crohn's disease, acquired hemolytic anemia, congenital hypoplastic anemia, erythroblastopenia, adult secondary thrombocytopenia, adult idiopathic thrombocytopenia purpura, acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute or chronic lymphocytic leukemia, Hodgkin's or non-Hodgkin's lynphomas, Waldenstrom's macroglobulinemia, primary brain tumors (adjunct), nephrotic syndrome, tuberculous meningitis, multiple sclerosis, myasthenia gravis. cerebral edema, chorioretinitis, diffuse posterior choroiditis, aleergic conjunctivitis, Herpes zoster ophthalmicus, anterior segment inflammation, iridocyclitis, iritis, keratitis, optoc neuritis, sympathetic ophthalmia, corneal marginal allergic ulcers, symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy and aspiration pneumonitis.
PharmacodynamicsPrednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthma, systemic lupus erythematosus, and many other inflammatory states. Prednisone has some mineralocorticoid activity and thus may affect ion exchange in the kidney.
Mechanism of actionPrednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflammation, interference in the function of mediators of inflammatory response, suppression of humoral immune responses, and reduction in edema or scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated. This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.
AbsorptionReadily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of absorption, Cmax, and exposure is comparable between formulations.
Volume of distributionNot Available
Protein bindingExtensively bound to plasma proteins.
Metabolism

Prednisone is completely converted to the active metabolite prednisolone by 11β-hydroxysteroid dehydrogenases. It is then further metabolized mainly in the liver. The exposure of prednisolone is 4-6 fold higher than that of prednisone.

SubstrateEnzymesProduct
Prednisone
PrednisoloneDetails
Route of eliminationExcreted in the urine as sulfate and glucuronide conjugates.
Half lifeHalf life of both the immediate- and delayed- release formulation is 2 to 3 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Prednisone Action PathwayDrug actionSMP00440
Prednisone Metabolism PathwayDrug metabolismSMP00631
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9918
Blood Brain Barrier + 0.9383
Caco-2 permeable - 0.5096
P-glycoprotein substrate Substrate 0.7861
P-glycoprotein inhibitor I Non-inhibitor 0.7847
P-glycoprotein inhibitor II Non-inhibitor 0.8383
Renal organic cation transporter Non-inhibitor 0.7463
CYP450 2C9 substrate Non-substrate 0.8496
CYP450 2D6 substrate Non-substrate 0.9138
CYP450 3A4 substrate Substrate 0.7407
CYP450 1A2 substrate Non-inhibitor 0.9406
CYP450 2C9 substrate Non-inhibitor 0.9072
CYP450 2D6 substrate Non-inhibitor 0.9418
CYP450 2C19 substrate Non-inhibitor 0.9253
CYP450 3A4 substrate Non-inhibitor 0.8902
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9095
Ames test Non AMES toxic 0.9132
Carcinogenicity Non-carcinogens 0.9597
Biodegradation Not ready biodegradable 0.925
Rat acute toxicity 1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.95
hERG inhibition (predictor II) Non-inhibitor 0.584
Pharmacoeconomics
Manufacturers
  • Schering corp sub schering plough corp
  • Roxane laboratories inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Halsey drug co inc
  • Bayer pharmaceuticals corp
  • Pharmacia and upjohn co
  • Ferndale laboratories inc
  • Solvay pharmaceuticals
  • Parke davis div warner lambert co
  • Schwarz pharma inc
  • American therapeutics inc
  • Amneal pharmaceuticals ny llc
  • Cm bundy co
  • Cadista pharmaceuticals inc
  • Contract pharmacal corp
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Marshall pharmacal corp
  • Mutual pharmaceutical co inc
  • Nylos trading co inc
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Rexall drug co
  • Sandoz inc
  • Scherer laboratories inc
  • Sperti drug products inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Udl laboratories inc
  • Upsher smith laboratories inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Vintage pharmaceuticals inc
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
Packagers
Dosage forms
FormRouteStrength
ConcentrateOral5 mg/mL
SolutionOral5 mg/5 mL
TabletOral1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 50 mg
Tablet, delayed releaseOral1 mg, 2 mg, 5 mg
Prices
Unit descriptionCostUnit
Sterapred DS 21 10 mg tablet Disp Pack64.0USDdisp
Prednisone powder3.36USDg
Sterapred ds 10 mg tablet unipak2.93USDtablet
Prednisone 5 mg/ml solution1.17USDml
PredniSONE 5 mg/5ml Solution0.5USDml
Prednisone 50 mg tablet0.47USDtablet
Prednisone 20 mg tablet0.29USDtablet
Prednisone 10 mg tablet0.27USDtablet
Prednisone 2.5 mg tablet0.25USDtablet
Prednisone 1 mg tablet0.23USDtablet
Apo-Prednisone 50 mg Tablet0.18USDtablet
Winpred 1 mg Tablet0.12USDtablet
Apo-Prednisone 1 mg Tablet0.11USDtablet
Prednisone 5 mg tablet0.08USDtablet
Apo-Prednisone 5 mg Tablet0.04USDtablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States64889602012-07-262020-03-14
United States66773262012-07-262020-03-14
United States83091242012-07-262024-04-23
United States83944072012-07-262024-04-23
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point230 - 235 °C (decomposes)MSDS
water solubilityVery slightly solubleMSDS
logP1.46MSDS
Predicted Properties
PropertyValueSource
water solubility1.11e-01 g/lALOGPS
logP2.07ALOGPS
logP1.66ChemAxon
logS-3.5ALOGPS
pKa (strongest acidic)12.58ChemAxon
pKa (strongest basic)-3.3ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count5ChemAxon
hydrogen donor count2ChemAxon
polar surface area91.67ChemAxon
rotatable bond count2ChemAxon
refractivity97.57ChemAxon
polarizability38.17ChemAxon
number of rings4ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterYesChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Jean Buendia, Michel Vivat, “Process for the production of prednisone 17.21-diacylates.” U.S. Patent US4601854, issued May, 1982.

US4601854
General Reference
  1. FDA label
External Links
ResourceLink
KEGG DrugD00473
KEGG CompoundC07370
PubChem Compound5865
PubChem Substance46508166
ChemSpider5656
ChEBI8382
ChEMBLCHEMBL635
Therapeutic Targets DatabaseDAP001041
PharmGKBPA451100
Drug Product Database868426
RxListhttp://www.rxlist.com/cgi/generic/pred.htm
Drugs.comhttp://www.drugs.com/prednisone.html
WikipediaPrednisone
ATC CodesA07EA03H02AB07H02AB15
AHFS Codes
  • 68:04.00
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(132 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe corticosteroid, prednisone, alters the anticoagulant effect, acenocoumarol.
Acetylsalicylic acidThe corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid.
AmbenoniumThe corticosteroid, prednisone, may decrease the effect of the anticholinesterase, ambenonium.
AmobarbitalThe barbiturate, amobarbital, may decrease the effect of the corticosteroid, prednisone.
AnisindioneThe corticosteroid, prednisone, alters the anticoagulant effect of anisindione.
AprobarbitalThe barbiturate, aprobarbital, may decrease the effect of the corticosteroid, prednisone.
Bismuth SubsalicylateThe corticosteroid, prednisone, may decrease the effect of the salicylate, bismuth subsalicylate.
ButabarbitalThe barbiturate, butabarbital, may decrease the effect of the corticosteroid, prednisone.
ButalbitalThe barbiturate, butalbital, may decrease the effect of the corticosteroid, prednisone.
ButethalThe barbiturate, butethal, may decrease the effect of the corticosteroid, prednisone.
ChlorotrianiseneThe estrogenic agent, chlorotrianisene, may increase the effect of corticosteroid, prednisone.
ClomifeneThe estrogenic agent, clomifene, may increase the effect of corticosteroid, prednisone.
Conjugated EstrogensThe estrogenic agent may increase the effect of corticosteroid, prednisone.
DicoumarolThe corticosteroid, prednisone, alters the anticoagulant effect of dicumarol.
DiethylstilbestrolThe estrogenic agent, diethylstilbestrol, may increase the effect of corticosteroid, prednisone.
Dihydroquinidine barbiturateThe barbiturate, dihydroquinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
EdrophoniumThe corticosteroid, prednisone, may decrease the effect of the anticholinesterase, edrophonium.
EstradiolThe estrogenic agent, estradiol, may increase the effect of corticosteroid, prednisone.
EstriolThe estrogenic agent, estriol, may increase the effect of corticosteroid, prednisone.
EstroneThe estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone.
EstropipateThe estrogenic agent, estropipate, may increase the effect of corticosteroid, prednisone.
Ethinyl EstradiolThe estrogenic agent, ethinyl estradiol, may increase the effect of corticosteroid, prednisone.
EthotoinThe enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, prednisone.
Fdecreases the effect of cortisone by metabolism alteration.
FosphenytoinThe enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, prednisone.
Glycerol PhenylbutyrateUse of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and glycerol pehnylbutyrate are used concomitantly.
HeptabarbitalThe barbiturate, heptabarbital, may decrease the effect of the corticosteroid, prednisone.
HexobarbitalThe barbiturate, hexobarbital, may decrease the effect of the corticosteroid, prednisone.
IndacaterolConcomitant therapy may increase the risk of hypokalemia via intracellular shunting. Monitor for adverse effects and especially for cardiovascular effects associated with hypokalemia.
Insulin LisproConcomitant therapy with corticosteriods may reduce the blood-glucose-lowering effect of insulin lispro.
ItraconazoleThe imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
KetoconazoleThe imidazole, ketoconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
LinagliptinCYP3A4 inducers may decrease levels of linagliptin and diminish the hypoglycemic effect of antidiabetic agents. Monitor concomitant therapy closely.
Magnesium salicylateThe corticosteroid, prednisolone, may decrease the effect of magnesium salicylate.
MephenytoinThe enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, prednisone.
MestranolThe estrogenic agent, mestranol, may increase the effect of corticosteroid, prednisone.
MethohexitalThe barbiturate, methohexital, may decrease the effect of the corticosteroid, prednisone.
MethylphenobarbitalThe barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, prednisone.
MidodrineIncreased arterial pressure
NeostigmineThe corticosteroid, prednisone, may decrease the effect of the anticholinesterase, neostigmine.
PentobarbitalThe barbiturate, pentobarbital, may decrease the effect of the corticosteroid, prednisone.
PhenobarbitalThe barbiturate, phenobarbital, may decrease the effect of the corticosteroid, prednisone.
PhenytoinThe enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, prednisone.
PrimidoneThe barbiturate, primidone, may decrease the effect of the corticosteroid, prednisone.
PyridostigmineThe corticosteroid, prednisone, may decrease the effect of the anticholinesterase, pyridostigmine.
QuinestrolThe estrogenic agent, quinestrol, may increase the effect of corticosteroid, prednisone.
Quinidine barbiturateThe barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, prednisone.
RifampicinThe enzyme inducer, rifampin, may decrease the effect of the corticosteroid, prednisone.
Salicylate-sodiumThe corticosteroid, prednisone, may decrease the effect of the salicylate, salicylate-sodium.
SalsalateThe corticosteroid, prednisone, may decrease the effect of the salicylate, salsalate.
SecobarbitalThe barbiturate, secobarbital, may decrease the effect of the corticosteroid, prednisone.
TacrineTacrine and Prednisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects.
TalbutalThe barbiturate, talbutal, may decrease the effect of the corticosteroid, prednisone.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Trisalicylate-cholineThe corticosteroid, prednisone, may decrease the effect of the salicylate, trisalicylate-choline.
VecuroniumVecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy.
WarfarinThe corticosteroid, prednisone, alters the anticoagulant effect of warfarin.
Food Interactions
  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.
  • When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state.

Targets

1. Glucocorticoid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Glucocorticoid receptor P04150 Details

References:

  1. Liu BG, Li ZY, Du M: [Effects of jingui shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients] Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Oct;26(10):881-4. Pubmed
  2. Friel PN, Alexander T, Wright JV: Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles—a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6. Pubmed
  3. Diez JJ, Iglesias P: Pharmacological therapy of Cushing’s syndrome: drugs and indications. Mini Rev Med Chem. 2007 May;7(5):467-80. Pubmed
  4. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K: Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6012-7. Pubmed
  5. Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res. 2006 May 15;12(10):3003-9. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

2. Corticosteroid 11-beta-dehydrogenase isozyme 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: ligand

Components

Name UniProt ID Details
Corticosteroid 11-beta-dehydrogenase isozyme 1 P28845 Details

References:

  1. Raza K, Hardy R, Cooper MS: The 11beta-hydroxysteroid dehydrogenase enzymes—arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford). 2010 Nov;49(11):2016-23. doi: 10.1093/rheumatology/keq212. Epub 2010 Jul 15. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Ferry JJ, Wagner JG: The nonlinear pharmacokinetics of prednisone and prednisolone. II. Plasma protein binding of prednisone and prednisolone in rabbit and human plasma. Biopharm Drug Dispos. 1987 May-Jun;8(3):261-72. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. Pubmed
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. Pubmed
  3. Dilger K, Schwab M, Fromm MF: Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004 Sep;10(5):578-83. Pubmed

2. Solute carrier organic anion transporter family member 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier organic anion transporter family member 1A2 P46721 Details

References:

  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11